There are exceptions, of course; however, all told, cancer-drug candidates are a sucker bet, IMHO.
Too often, I feel that way about most, if not all, biotech stocks. The real winners have beem few and far between. For every AMGN, BIIB, GILD, etc., there have been probably twenty that have come and gone. Bty it sure has been fun to follow.